{"analyses":[{"ciLowerLimit":"0.97","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.26","estimateComment":"Comparison: \"Tertile 1 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1194","paramType":"Odds Ratio (OR)","paramValue":"1.11","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","estimateComment":"Comparison: \"Tertile 1 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7004","paramType":"Odds Ratio (OR)","paramValue":"1.03","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.26","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.49","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"1.37","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.16","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.38","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"1.26","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.03","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.34","estimateComment":"Comparison: \"Tertile 2 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0134","paramType":"Odds Ratio (OR)","paramValue":"1.17","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.96","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.25","estimateComment":"Comparison: \"Tertile 2 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1592","paramType":"Odds Ratio (OR)","paramValue":"1.10","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.24","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.47","estimateComment":"Comparison: \"Tertile 2 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"1.35","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.14","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.36","estimateComment":"Comparison: \"Tertile 2 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"1.25","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.03","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.33","estimateComment":"Comparison: \"Tertile 3 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0131","paramType":"Odds Ratio (OR)","paramValue":"1.17","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.95","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.22","estimateComment":"Comparison: \"Tertile 3 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2731","paramType":"Odds Ratio (OR)","paramValue":"1.07","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"1.06","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.28","estimateComment":"Comparison: \"Tertile 3 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0012","paramType":"Odds Ratio (OR)","paramValue":"1.16","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.98","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","estimateComment":"Comparison: \"Tertile 3 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, alcohol consumption, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1477","paramType":"Odds Ratio (OR)","paramValue":"1.07","statisticalMethod":"Conditional Logistic Regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"178334"},{"groupId":"OG001","value":"1704443"}]}],"title":"Never (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"2175"}]}],"title":"Tertile 1 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"2163"}]}],"title":"Tertile 2 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"2169"}]}],"title":"Tertile 3 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"177409"},{"groupId":"OG001","value":"1698480"}]}],"title":"Never (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"620"},{"groupId":"OG001","value":"4213"}]}],"title":"Tertile 1 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"587"},{"groupId":"OG001","value":"4104"}]}],"title":"Tertile 2 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"522"},{"groupId":"OG001","value":"4153"}]}],"title":"Tertile 3 (without 2 year lag)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"179138"},{"groupId":"OG001","value":"1710950"}],"units":"Participants"}],"description":"Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).","groups":[{"description":"Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008","id":"OG000","title":"Incident All-cancer Patients"},{"description":"Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site","id":"OG001","title":"Matched Controls for Incident All-cancer Patients"}],"paramType":"NUMBER","populationDescription":"Cases \\& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.","reportingStatus":"POSTED","timeFrame":"The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.","title":"Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin","type":"PRIMARY","unitOfMeasure":"participants"}